Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary (MESA-COPD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01397721|
Recruitment Status : Unknown
Verified April 2015 by R. Graham Barr, Columbia University.
Recruitment status was: Active, not recruiting
First Posted : July 20, 2011
Last Update Posted : April 23, 2015
|Condition or disease|
|Chronic Obstructive Pulmonary Disease|
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in the US and will soon replace stroke as the third leading cause.
Translation of promising biological hypotheses of COPD pathogenesis to human populations that may lead to new therapies is urgently needed. The vascular hypothesis of COPD was articulated almost 50 years ago. Bench research on endothelial dysfunction in COPD is evolving rapidly and has shown that acrolein in cigarette smoke causes endothelial apoptosis and endothelial apoptosis is directly implicated in COPD pathogenesis. Clinical studies on endothelial dysfunction and vascular changes in COPD are limited.
The proposed study is a longitudinal study of smokers nested among the MESA-Lung (AAAA7791) and EMphysema and Cancer Action Project (EMCAP) Studies (AAAA6484), which together provide a well-defined cohort of 4,617 participants with prior spirometry and CT measures.
The Multiethnic Study of Atherosclerosis - Chronic Obstructive Pulmonary Disease (MESA COPD Study) has two main scientific purposes:
- characterize the pulmonary vascular changes in COPD and their biology, and
- propose novel pathways for new therapies in COPD.
MESA COPD is a longitudinal study of smokers nested within the MESA-Lung and EMCAP cohorts of 360 participants (160 cases with mild, 60 cases with moderate and 40 cases with severe COPD and 100 controls) who will be phenotyped with magnetic resonance (MR) pulmonary angiography, pulmonary function testing, full-lung CT scans, serum Vascular Endothelial Growth Factor (VEGF), cell assays and gene expression profiling. MESA COPD Study will contribute improving the knowledge of early changes in COPD that may lead to novel disease-modifying medical therapies and preventative strategies.
|Study Type :||Observational|
|Actual Enrollment :||360 participants|
|Official Title:||Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary (MESA-COPD)|
|Study Start Date :||May 2009|
|Estimated Primary Completion Date :||March 2016|
|Estimated Study Completion Date :||July 2016|
- Changes in cardiac structure and pulmonary vascular structure and function [ Time Frame: Up to 2 years from start of study ]
Cardiac structure: changes in right ventricular (RV) mass, RV mass/Right Ventricular End-Diastolic Volume (RV-EDV)
Pulmonary structure: changes in total pulmonary vascular volume (TPVV) and pulmonary artery (PA) perfusion
Function: changes in PA flow and distensibility
- Numbers of CD31+/CD42 endothelial microparticles (EMPs) [ Time Frame: Up to 2 years from the start of study ]Numbers of CD31+/CD42 EMPs reflective of apoptosis are elevated; They are abnormal in severe, moderate and mild COPD compared to controls.
- Numbers of circulating endothelial cells (CEC) [ Time Frame: Up to 2 years from the start of study ]Numbers of circulating endothelial cells (CEC), resulting from endothelial injury, are elevated. They are abnormal in severe, moderate and mild COPD compared to controls
- Numbers of endothelial progenitor cells (EPCs), involved in endothelial repair, are decreased [ Time Frame: Up to 2 years from the start of study ]They are abnormal in severe, moderate and mild COPD compared to controls.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01397721
|United States, New York|
|New York, New York, United States, 10032|
|Principal Investigator:||R. Graham Barr, M.D., Dr.PH.||Columbia University|